MLTX — MoonLake Immunotherapeutics
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1821586 ·
Last close
$18.44
Market Cap
$1.57B
52W High
$23.29
52W Low
$15.76
ADV30
1,365,773
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -70,024,000 | -69,707,000 | 400,374,000 | 298,490,000 | 146,350,000 |
| Dec 2025 | 0 | — | -65,218,000 | -62,427,000 | 424,433,000 | 334,517,000 | 119,952,000 |
| Sep 2025 | 0 | — | -71,434,000 | -69,729,000 | 414,335,000 | 350,736,000 | 123,144,000 |
| Jun 2025 | 0 | — | -60,698,000 | -55,220,000 | 460,096,000 | 306,681,000 | 102,152,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-224,153,000
Investing CF
$146,844,000
Financing CF
$103,519,000
CapEx
$-342,567
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-3.58
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-532,618,000
Inventory
—
Receivables
$5,763,000
ST Investments
$59,431,000
EBIT TTM
$-248,892,000
Pretax Income TTM
$-258,390,000
Interest Exp TTM
$9,498,000
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -244,834,000 | -227,318,000 | 424,433,000 | 119,952,000 | — | -196,007,000 |
| Dec 2024 | 0 | -143,091,000 | -118,936,000 | 477,933,000 | 24,542,000 | — | -116,587,000 |
| Dec 2023 | 0 | -54,123,000 | -36,007,000 | 526,540,115 | 13,049,096 | — | -42,778,000 |
| Dec 2022 | 0 | -65,061,417 | -49,973,249 | 76,843,301 | 8,076,603 | — | -55,893,900 |
TTM Snapshot
Revenues TTM
$-141,718,488
NetIncome TTM
$-55,278,174
OpCashFlow TTM
$0
Assets (Latest)
$477,933,000
Forward EPS
$-3.37
Max Pain — expiry 2026-08-21
max pain strike: $19.00 · spot: $18.44 · call oi: 20,394 · put oi: 7,696
Expected Move to 2026-08-21:
±$6.28
(34.03%) —
implied range
$12.17 –
$24.72
· ATM straddle on $18.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SRPT | Sarepta Therapeutics, Inc. | $1.57B | $14.86 | — |
| FBRX | Forte Biosciences, Inc. | $1.57B | $76.60 | — |
| ANAB | ANAPTYSBIO, INC | $1.58B | $53.36 | — |
| SEPN | Septerna, Inc. | $1.55B | $34.45 | — |
| INVA | Innoviva, Inc. | $1.55B | $20.97 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
2026-07-31 13:55 · Yahoo
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears
2026-07-13 02:48 · Yahoo
MoonLake Immunotherapeutics' CFO Sells 39K Shares
2026-07-03 14:34 · Yahoo
MoonLake Immunotherapeutics (MLTX) Outlook Strengthens as Analysts See Major Opportunity in Hidradenitis Suppurativa
2026-06-30 13:22 · Yahoo
How Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On Offering
2026-06-25 12:07 · Yahoo
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
2026-06-25 00:09 · Yahoo
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Easing US-Iran Tensions
2026-06-24 13:17 · Yahoo
MLTX Stock Extends Pullback After Biggest Rally In Over 6 Months Following Skin Disease Trial Data — A Look At The Latest Development
2026-06-24 11:48 · Yahoo
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
2026-06-24 03:08 · Yahoo
MLTX Stock Clocks Best Day In Over 6 Months — What’s Driving The Investor Optimism?
2026-06-22 20:59 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.